New therapeutic strategy of fludarabine-resistant relapsed and refractory chronic lymphocytic leukemia
10.3760/cma.j.issn.1009-9921.2013.09.004
- VernacularTitle:氟达拉滨耐药的复发难治性慢性淋巴细胞白血病的治疗策略
- Author:
Lihua QIU
;
Huaqing WANG
- Publication Type:Journal Article
- Keywords:
Leukemia,lymphocytic,chronic;
Relapsed;
Refractory;
Therapy
- From:
Journal of Leukemia & Lymphoma
2013;22(9):520-523
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) remains an incurable disease.Rituximab and fludarabine are two of the most effective agents in CLL update.Despite the widespread use of highly effective chemoimmunotherapy,fludarabine-refractory CLL remains a challenging problem associated with poor overall survival.Approved therapeutic options for these patients remain limited.Fortunately,allogenetic stem cell transplantation (allo-SCT) and several novel targeted therapeutics in clinical trails hold promise of significant benefit for these patients' population.This review discusses the activity of available and novel targeted therapeutics besides allo-SCT in fludarabine-refractory or fludarabine-resistant CLL.
